Seroconversion rates were 88.5 % and 92.9 %, respectively.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Immunogenicity of a recombinant yeast derived (containing no pre-S gene products) hepatitis B vaccine (Engerix B) and recombinant mammalian cell-derived (containing pre-S gene products) hepatitis B vaccine (GenHevac B) was investigated on health care personnel working at Alsancak State Hospital.
Conclusion & Impact:Seroconversion rates were 88.5 % and 92.9 %, respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Immunogenicity of a recombinant yeast derived (containing no pre-S gene products) hepatitis B vaccine (Engerix B) and recombinant mammalian cell-derived (containing pre-S gene products) hepatitis B vaccine (GenHevac B) was investigated on health care personnel working at Alsancak State Hospital. The yeast-derived vaccine and mammalian cell-derived vaccine induced anti-HBs seroconversion. Seroconversion rates were 88.5 % and 92.9 %, respectively.
Özet
Alsancak Devlet Hastanesi sağlık personelinde, pre-S gen ürünlerini içeren memeli hücresi kökenli (GenHevac B) ve içermeyen maya kökenli (Engerix B) hepatit B rekombinan aşılarının immünojenitesi araştırılmıştır. Pre-S gen ürünleri içermeyen maya kökenli aşı ile % 88.5, pre-S gen ürünleri içeren memeli hücresi kökenli aşı ile % 92.9 serokonverziyon saptanmıştır.
🔖
Cite This Article
GÜNER, S., ÖZACAR, T., BİLGİÇ, A., KUMOVA, D., TÜRKER, T. T. (2022). Immunization results determined with two different Hepatitis B vaccine on health care personnel. İnfeksiyon Dergisi, Cilt: 10 - Sayı: 2, 111–113. https://ajindex.com/articles/547160